Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.
Fundamentals
Mkt Cap
$16.26M
Volume
-
52W High
$33.60
52W Low
$3.02
PE Ratio
-0.03
Avg. Volume
81,405.42
EPS (Annual)
-
P/B
0.87
Rev/Employee
$0.00
Earnings
-
52
Neutral Sentiment
How do you feel about AKTX?
BioResearcher
$AKTX
This new data shows their drug can slow down tumor growth for those have already built resistance to current approved ADC drugs:
2
1
focafoca99
$AKTX discusses its differentiated PH1 ADC payload strategy and plans Phase 1 for AKTX-101 by mid-2027.
2
BioResearcher
$AKTX
Big pharm are focusing on ADC because ADC will become standard of care for cancers:
This recent article explains:
2
BioResearcher
$AKTX
This new article explains why drug resistance has become a crisis for big pharma:
and why big pharm are buying small ADC companies to address the resistance problems:
2
ABinterceptor
$AKTX Can anyone explain the trajectory of this stock? What are the catalysts? Thank you.
focafoca99
$AKTX amended its CEO agreement, boosting the chief's base salary to $625,000, raising bonus potential and granting RSUs and options.